Fifty percent of diabetics (7% of general population) suffer from peripheral arterial occlusive disease, which may lead to amputation due to critical limb ischemia (CLI). The aim of our study was to prevent major limb amputation (MLA) in this group of patients using a local application of autologous bone marrow stem cells (ABMSC) concentrate. A total of 96 patients with CLI and foot ulcer (FU) were randomized into groups I and II. Patients in group I (n = 42, 36 males, 6 females, 66.2 ± 10.6 years) underwent local treatment with ABMSC while those in group II (n = 54, control, 42 males, 12 females, 64.1 ± 8.6 years) received standard medical care. The frequency of major limb amputation in groups I and II was 21% and 44% within the 120 days of follow up, respectively (p < 0.05). Only in salvaged limbs of group I both toe pressure and toe brachial index increased (from 22.66 ± 5.32 to 25.63 ± 4.75 mmHg and from 0.14 ± 0.03 to 0.17 ± 0.03, respectively, mean ± SEM). The CD34 + cell counts in bone marrow concentrate (BMC) decreased (correlation, p = 0.024) with age, even though there was no correlation between age and healing. An unexpected finding was made of relative, bone marrow lymphopenia in the initial bone marrow concentrates in patients who failed ABMSC therapy (21% of MLA). This difference was statistically significant (p < 0.040). We conclude ABMSC therapy results in 79% limb salvage in patients suffering from CLI and FU. In the remaining 21% lymphopenia and thrombocytopenia were identified as potential causative factors, suggesting that at least a partial correction with platelet supplementation may be beneficial.
INTRODUCTION
suddenly and causes 50-67% of all nontraumatic lower extremity amputations. Fifty-two percent of diabetics with CLI die during the 4.5 year follow up (35, 36) . In diabetic patients, nonhealing cutaneous ulcers are a significant clinical, social, and healthcare problem.
Standard treatment of chronic wounds, and especially those secondary to CLI, includes surgical revasculariza-Based on more than 10 million diabetic patients in the US and an estimated prevalence of 15% for chronic cu-tion (distal crural or pedal bypass), endovascular therapy (recanalization by percutaneous transluminal angioplasty), taneous ulcers, there are approximately 1.5 million patients with this problem. Peripheral arterial occlusive or maximum podiatric wound care (hyperbaric oxygen, antibiotics, vasodilators). Despite the available thera-disease (PAOD) has been recognized as a significant factor in this population. For example, in European pies, 25% of patients still progress to amputation. The outcomes are even worse in diabetics, with multicausal Study Group on Diabetes and Lower Extremity (Eurodiale) 49% of patients presenting with new diabetic foot disease, where neuropathy, poor healing, and peripheral arterial occlusive disease occur simultaneously. Thirty ulcer had PAOD. Critical limb ischemia (CLI) develops percent of such patients require amputation, and 25% of 10.6 years) underwent local treatment with ABMSC while group II (n = 54, 42 males, 12 females, 64.1 ± 8.6 them die (8, 15) . The introduction of novel experimental therapies using recombinant growth factor therapy com-years) received a standard care and served as controls. bined with tissue grafting has shown minimal benefit
Patients and Follow-up over standard treatment (23, 24) .
All patients were examined prior (at 0) and at 90 and Building on the existing experience with autologous 120 days following the therapeutic procedures (ABMSC stem cell progenitors and various platelet preparations, therapy or standard treatment). The number of patients we present a potential explanation for the difficulties with diabetes, hyperlipidemia, and ischemic heart displaguing cellular therapies and introduce an improved ease were significantly higher in group II than in group modality for multicellular therapy (3, 20, 38, 40) . The pro-I (p = 0.040, p = 0.011, p = 0.044, respectively) (Table cess of angiogenesis requires not only the initial induc-1). Wound defects were assessed according to the Unition of tissue degradation followed by vascular sproutversity of Texas Wound Classification and equally dising, but also the stabilization of early vascular sprouts tributed between treatment groups ( Table 2) . by pericytes and remodeling and reconnection to the sur-Patient inclusion criteria were: (a) CLI as defined by rounding ischemic tissue to the periphery of new vessel ankle/brachial index ≤0.4, and ankle systolic pressure wall. Thus, the process of vessel maturation and mainte-≤50 mmHg or toe systolic pressure ≤30 mmHg; (b) over nance requires spatially and temporally controlled re-18 years of age suffering from chronic and critical limb lease of different pro-and antiangiogenenic growth facischemia according to the TASC classification Ruthertors in the local milieu of the wound. While the initial ford 4-6, Fontaine IV, (c) with signed informed consent, vascular sprout is dependent on a strong VEGF concen-(d) failed basic conservative and revascularization treattration gradient, as vessels mature, their dependence on ment (surgical or endovascular). VEGF decreases. The recruitment of pericytes and sub-Patient exclusion criteria were: (a) estimated survival sequent stabilization of vascular wall and perivascular less than 6 months, (b) known bone marrow diseases healing is dependent mainly on PDGF and angiopoietin (e.g., lymphoma, leukemia, myelodysplastic syndrome, 1 (5) (6) (7) 10) . metastasis in the bone marrow), (c) end stage renal fail-Wound healing and tissue remodeling may take up to ure and on dialysis, (d) acute stage of severe limb ische-8-12 weeks depending on degree of the initial tissue mia with severe inflammatory process affecting the paischemia and hypoxia. Here we show that this process tient's life that requires limb amputation to avert grave can be accelerated by the autologous bone marrow stem outcome. cell injection, resulting in marked improvement of out-
The primary endpoints for both treatment groups comes. The autologous nature of cell therapy described were major limb amputation (MLA) during 120 days herein appears to be effective for reperfusion up to cerand a degree of pain and function (assessed by clinical tain degree of ischemic tissues (30, 44, 46) . Given that examination at pretreatment (day 0) and at a 90 and 120 tissue healing and remodeling is associated with angioday follow-up intervals. genesis, and that angiogenesis requires an orchestrated interaction of different cells, we postulate that an injection of bone marrow concentrate enriched not only in February 10, 2009) and randomized into groups I or II. disease, respectively, were significantly higher in group II than in group I (p = 0.040, p = 0.011, p = 0.044, respectively).
Patients in group I (n = 42, 36 males, 6 females, 66.2 ± of bone marrow concentration also decreases the proportion of RBCs in the final concentrate (18). Thereafter, 40 ml of final bone marrow concentrate (BMC) was drawn from centrifuge containers into a syringe and im-The secondary endpoints were only performed in group I and included measurements of circulatory and mediately applied by 40 injections, each ϳ1 ml, into the ischemic limb along the posterior and anterior tibial ar-blood parameters, such as Laser Doppler flowmetry with PeriFlux System 5000 (Perimed AB, Järfälla, Stock-tery. The entire treatment procedure took less than 1 h. holm, Sweden), measurements of transcutaneous oxygen Statistical Analysis (TcpO 2 ), CO 2 (TcpCO 2 ) levels with challenge test (O 2 inhalation 5l/min/10 min), ankle/brachial index (ABI), Statistical analyses of all data set were performed with SPSS software version 15.0 for Windows (SPSS toe pressure (TP, mmHg), toe brachial index (TBI), and skin perfusion pressure (SPP, mmHg) (39) . They were Inc., CR). A two-sided value of p < 0.05 was considered statistically significant for all analyses. Continuous vari-measured at baseline prior (day 0) and 90 and 120 days after the ABMSC therapy. All measurements were done ables are presented as mean ± SEM or as median (interquartile) in box-and-whisker plots. The differences in according to the standard procedure described by Shefield et al. (39) 1 cm above the wound, avoiding veins.
the major endpoints between groups I and II were compared by Mann-Whitney Rank Sum Test. Categorical In addition, peripheral blood tests such as white blood cell counts, differential counts, fibrinogen, CRP, and variables are stated with frequency and percentage. Chisquare test or Fisher's Exact Test were used to compare platelets count levels were performed. In patients (group I) bone marrow aspirate (BMA) and bone marrow con-categorical data. The statistical analysis included simple (Pearson's) correlation and nonparametric correlation by centrate (BMC) were also analyzed to assess the number of CD34 + progenitor cells (×10 9 /L), platelets, neutro-means of Spearman's rho. phils, lymphocytes, monocytes, eosinophils, and baso-RESULTS phils. External wound characteristics were documented by photography and clinical examination (swelling, Patients were randomized to the respective treated (group I) and control (group II) groups, as indicated and color, diameter) and correlated with the degree of initial ischemia, hypoxia, pain level, and claudication interval the former were subjected to the ABMSC treatment procedure. At 120 days of follow-up the frequency of major using EQ-50 quality of life questionnaire. Follow-up angiography was performed at 120 postoperative days. The limb amputations (MLAs) was significantly (p < 0.05) lower in group I than in group II (21% vs. 44%, respec-term full healing refers to reestablishment of skin barrier with no exposure of subepidermal tissues. Wound refers tively). Interestingly MLA (21%) was necessary only in those group I patients suffering from significant lympho-to any, even minimal exposure of subepidermis. Minor amputation refers to amputation that does not affect penia and thrombocytopenia in BMC at the time of treatment. Forty-two patients in group I finished 90 days fol-weight-bearing capability. Nonhealing refers to the defect remaining the same size or progressing in depth or low-up and 37 patients in group II finished 120 days of follow-up. Five patients in group I and eight in group II diameter.
died of causes unrelated to the therapy or CLI, mostly ABMSC Therapeutic Procedure coronary heart disease. No patient was lost or withdrawn from the study. The ABMSC procedure included surgical preparation, harvesting of bone marrow (BM), isolation of Characteristics of Patients in Group I ABMSCs from the bone marrow aspirate, and their local application. Bone marrow was collected from both iliac Out of 42 patients, 37 were diabetics; from those, 31 (73.8%) were on insulin, 1 (2.38%) was on oral hypo-bone crests according to the standard Jamshidi puncture glycemic agents, and 5 (11.9%) patients were managed presented as a comparison between healing and nonhealing patients. Patients in group I who healed showed sig-conservatively. Patients had history of 50 revascularization procedures such as proximal bypasses (7 aortofem-nificant improvements (p < 0.05) in SPP, LDP alone, and LDP heat values at 90 days compared to baseline oral or femoropopliteal), distal bypasses (4 crural or pedal), proximal PTA with stent procedures (9), crural measurements (Table 3) . Correspondingly, toe pressure and toe brachial index increased from baseline of (22.66 ± or pedal PTA recanalizations (28) , and lumbar sympatectomies (2) before ABMSC therapy. In addition some 5.32 and 0.14 ± 0.03 mmHg, respectively, to 25.63 ± 4.75 and 0.17 ± 0.03, respectively, at 90 days. While of these patients had history of contralateral major limb amputation (17 patients), contralateral minor amputation there were no significant differences in TcpCO 2 levels between healed and not healed limbs at 90 days, the (1 patient), and index limb minor amputation (17 patients). In this group 17 patients were in stage DIII ac-nonhealing group had worse TcpCO 2 following that interval, and exceeded 40 mmHg. cording to University of Texas Wound Classification.
Neutrophil counts in peripheral blood samples in
Characteristics of Patients in Group II (Controls)
group I patients were not significantly different in patients who healed versus those who did not. In contrast, Fifty-four patients in this group suffered from CLI and diabetic foot ulcer; 39 of them were in stage DIII C-reactive protein was significantly elevated (p < 0.05) in patients with poorly healed limb 30 days postinter-according to University of Texas Wound Classification. Out of 54 patients, 46 patients had a history of revascu-vention. Lymphocyte counts dropped significantly (p < 0.05) immediately following the procedure (day 3, 7, larisation procedure such as endovascular recanalization (39) , aortobifemoral bypass (1), distal pedal bypass (1), 14) and remained low 30 days later (Table 4 ).
There was a significant correlation between low femoropopliteal bypass (4), and embolectomy (1).
CD34 + cell counts in the bone marrow concentrate Group I ABMSC Patients (BMC) and increasing age (Spearman's rho = −0.348, p = 0.024), even though there was no difference in Based on the degree of ischemia on day 0 (assessed by Laser Doppler flow), patients in group I were divided CD34 + cell counts between patients who healed or those who did not (Fig. 1 ). The SmartPreP2 centrifuge gradi-into light (4.76%), moderate (64.29%), and severe (30.95%) ischemia group. Similarly, hypoxia measure-ent density centrifugation resulted in at least a fivefold concentration of CD34 + cells in the bone marrow con-ment (by TcpO 2 measurements) resulted in subdivision to normal (7.14%), light (19.05%), moderate (59.52%), centrate and more than 3.8-fold concentration of platelets (compared to a sample of BMA aspirate before cen-and severe (14.29%) hypoxia groups. The results are . Both SPP and ankle brachial index (ABI) were significantly (p < 0.05) higher at baseline in patients who healed versus those who did not. There was gradual improvement in SPP, LDP, and ABI that became statistically significant (p < 0.05) at 90 days following ABMSC treatment in patients who healed versus those who did not (Group I). *p < 0.05 versus baseline value. †p < 0.05 versus healed group of patients. Values are mean ± SEM for healing (Yes) and nonhealing (No). Analysis of peripheral blood was done at baseline and at 0, 3, 7, 14, and 30 days. Significant differences were found in the number of lymphocytes, and CRP between healing and nonhealing patients. Circulating C-reactive protein levels were significantly higher on day 3, 7, and 30 (p = 0.029, p = 0.009, and p = 0.010, respectively) in patients who did not heal. Lymphocyte counts were significantly lower on day 0, 3, 14, and 30 (p = 0.018, p = 0.036, p = 0.021, and p = 0.002, respectively) in the early stages of treatment, than those of patients that healed well (Group I). Figure 1 . CD34 + counts decrease with age (A) but the decrease in CD34 + cell count does not correlate with wound nonhealing (B). A significant correlation between decreasing CD34 + in BMA and advancing age was found and was consistent with the previously published data on SC aging and SC count lowering with age (Spearman's rho = −0.348, p = 0.024). Yet, we did not find the often extrapolated effect on healing. There was no statistical difference between the healing and nonhealing group and CD34 + counts (p = 0.873) in group I. We observed one extreme outlayer (marked as * 12 in B). trifugation). A detailed analysis of cells counts in BMC −0.549, p = 0.010) of patients with a healing limb, while it did not exist in patients with a poorly healed limb after centrifugation is shown in Table 5 . Patients who healed poorly exhibited significant lymphopenia (p < (Spearman's rho = −0.324, p = 0.434) (Fig. 4A, B ). As shown in representative images of the character 0.05) in the initial BMC ( Fig. 2A) , even though no correlation between lymphopenia in BMC and diabetes was and wound diameter of healing limbs, a complete wound closure and skin integrity was achieved by 90 days (Fig.  appreciated (Fig. 2B ).
In the majority of patients with the nonhealing limb, 5). Capillary angiogenesis is demonstrated by a decrease in the degree of initial ischemia/hypoxia. Improvement platelet and CD34 + cells were low in the initial bone marrow aspirate, and did not show the direct monoto-in overall vascularity was further demonstrated by follow-up angiography at 120 days (Fig. 6 ). nous (nonlinear) dependence of CD34 + cell concentration and platelets. In healing patients a higher CD34 + Pain was evaluated using the previously validated EQ-50 quality of life questionnaire. Patients undergoing cell concentration corresponds to higher concentration of platelets (Spearman's rho = 0.679, p = 0.006) ( Fig. ABMSC procedure reported a subjective improvement in ischemic pain within 72 h following the cellular ther-3A, B). Patients with low platelet counts in the group of patients that healed had higher levels of VEGF than pa-apy. However, only patients with healing limbs experienced a sustained long-term (180 days) control of their tients with low platelet counts in the nonhealing group. Thus, there was a statistically significant correlation of pain, and this difference was statistically significant at 90 days (p < 0.05). VEGF (pg/ml) and concentration of platelets in BMC (r = The values are mean ± SEM from 42 patients (Group I). Total cell counts were performed in bone marrow aspirates and concentrates produced with SmartPReP2 gradient density centrifugation. Figure 2 . Lymphopenia in the initial BMC was evident in patients who did not heal despite ABMSC transplantation. Only patients with significant baseline lymphopenia and thrombocytopenia (p < 0.05) in the bone marrow aspirate and concentrate went on to a major limb amputation (21% of group 1), compared to healed patients (79%) (A). The low lymphocyte counts were not due to the underlying diabetes (B) and represented a distinct immune defect. We observed one extreme outlayer marked as * 2 and outlayers o 19 and o 2 with higher lymphocytes count.
DISCUSSION
of wound healing was unclear. Our results suggest that multicellular therapy using ABMSC from bone marrow aspirate maximizes the reciprocal interactions between Cell therapies with pure progenitor cells or with mononuclear cell concentrates have shown significant im-the various transplanted cells of the bone marrow, as well as the interaction of these cells with the extracellu-provement in the healing of chronic ulcers (1, 2, 22, 26, (31) (32) (33) 43) . While the outcomes for mononuclear cell lar matrix (ECM). The principle of "dynamic reciprocity dialogue" between the cells and their microenvironment therapy were noticeably better than for therapy using only one cell type, the mechanism for this enhancement acts as a circuitry by which tissue architecture and func- Figure 3 . Correlation between number of CD34 + cells and number of platelets in bone marrow concentrate. A comparison of a subgroup of patients treated with ABMSCs that healed versus those that did not revealed a significant direct monotonous (nonlinear) dependence of platelets on CD34 + cell concentration; that is, a higher CD34 + cell concentrations correspond to higher concentration of platelets (Spearman's rho = 0.679, p = 0.006) (B). In addition, the majority of patients that did not heal clustered in lower left corner, indicating low platelet and CD34 + cells. In contrast, the group of patients that healed showed a wide distribution of relative ratios of platelets and CD34 + cells (A).
Figure 4.
Patients with significant lymphopenia, thrombocytopenia, and low levels of VEGF in BMC did not respond well to ABMSC therapy. All limbs in this patient population were amputated (21%) within 120 days after ABMSC treatment. As evident, the combination of low platelet counts and low VEGF levels is associated with poor healing (A). Statistically significant correlation (r = −0.549, p = 0.010) only exists between the number of platelets and VEGF level in the group of patients treated with ABMSCs who had improved circulation and healed, but not in those without healing (r = −0.324, p = 0.434) (B).
tion become integrated (34) . Thus, even a relative defi-but the majority of healing patients were gathered at moderate concentrations of both platelets and CD34 + ciency in one of the cellular components can result in severe defect in the wiring of this circuitry, and derail cells in proportional concentrations rather than at either of the extremes. Viewed in combination with the obser-the signaling axis that transmits through, and is regulated by, the interaction of the individual cell cytoskele-vation that as long as patients with low platelet count also have high concentration of VEGF ( Fig. 4) they can ton and the integrins of the underlying matrix.
The tissue microenvironment undergoes extensive re-heal, a model of dynamic reciprocity compensating for individual deficiencies of growth factors emerges. modeling during tissue regeneration and involves the deposition, degradation, and structural reorganization of The analysis of peripheral blood and bone marrow revealed significant differences between patients with ECM components. The influence of ECM on the individual cell components within the microenvironment healing and nonhealing limbs. Circulating levels of Creactive protein were significantly higher in patients provides morphogenic cues to control cell survival, proliferation, migration, polarization, and differentiation. who did not heal, particularly in the early postprocedural period (Table 4 ). This may be a reflection of an underly-Similarly, each of the cell components provides specific cues for the restructuring of the extracellular matrix. A ing chronic inflammatory state of the patient, or an excessive inflammatory response. Because the levels of C-bone marrow cell concentrate, such as the one used in our study, is enriched in platelets, which provide the ve-reactive proteins were high even on day 0, an underlying chronic inflammatory state is more likely. This would be hicle for cell-cell interaction. Intact platelets provide a source of angiogenesis growth regulators, which can be consistent with the finding of significantly lower initial lymphocytes levels in patients that did not heal well (Ta-released in response to tissue-specific stimuli (21, 25) . The sequential, spatially, and temporally controlled re-ble 4). A corresponding statistically significant (p < 0.05) lymphopenia and thrombocytopenia was evident lease of stimulators and inhibitors of angiogenesis from platelets may explain the improved outcomes with com-in the BMC of patients that healed poorly versus those that healed well ( Figs. 2A and 3) , yielding further sup-plete cellular therapy compared to CD34 + cell pure therapy, mononuclear cell therapy, or therapy with recombi-port to importance of these cellular factors in wound healing and regeneration. While the role of platelets in nant proteins (4, 11, 19, 24) . The majority of nonhealing patients clustered at low concentrations for both platelets adhesion, maturation, and differentiation of stem cell progenitors has been well documented, the role of lym-and CD34 + cells ( Fig. 3 ), suggesting that there was not an optimal concentration that would permit healing. The phocytes in the local wound microenvironment has only been suspected (12, 28, 29, 42) . Whereas an immune de-ratio of platelets and CD34 + cells was highly variable, fect is often correlated with an underlying chronic con-peripheral blood mononuclear cells (PBMNC) along with platelets resulted in significantly improved perfu-dition, in this study the lymphopenia in the initial BMC did not correlate with the presence of diabetes ( Fig. 2A , sion than that achieved by PBMNC, platelets, or polymorphonuclear cells alone (16, 17) . As shown by Langer B), and may represent a distinct immune defect. We show, possibly for the first time, that the lymphopenia et al., endothelial cell progenitors require platelets for their homing, adhesion, and differentiation (28), strongly is not a feature of diabetes, but rather a prognostic factor evident at baseline (27) .
supporting our evidence for the dynamic interaction of endothelial cell progenitors and platelets (Fig. 3) . The Our findings on the role of platelets in progenitor engraftment are supported by preclinical studies in mice gradient density centrifugation increased the concentration of platelets about 3.9-fold while preserving the rela-with critical limb ischemia where the administration of Figure 5 . Representative photographs of limb ulcers before and 90 days after ABMSC therapy. During 90 days after ABMSC therapy all ulcers associated with CLI healed in those patients (100%) with normal lymphocyte and thrombocyte counts in BMC at the time of procedure. enon in tissue regeneration and supports our abovestated hypothesis that it is not the absolute number of the cells present, but rather their ability to interact with other cells in the microenvironment and the availability of other collaborating cells (9,37,45).
In diabetic patients commonly used methods such as ankle/brachial index may be less informative because of significant atherosclerosis and vessel calcification rendering the vessels incompressible. For this reason we have used a number of methods to evaluate the improvements in ischemic limb perfusion and healing, such as skin perfusion pressure (SPP), laser Doppler perfusion (LDP), transcutaneous capillary pressure of oxygen (TcpO 2 ), toe pressure (TP), and transcutaneous capillary pressure of CO 2 (TcpCO 2 ) ( Table 3 ). Skin perfusion pressure measurement is more accurate in diabetic patients than ABI. Among all of the methods used in our study, the combination of LDP and TcpO 2 provided excellent information about the local blood perfusion and oxygenation and reflected improvements in limb healing better than other methods. TcpCO 2 may provide quantifiable information about metabolic status of the leg and predict a catabolic risk.
There were some differentiating characteristics between patients who healed and those that did not. Patients with high circulating neutrophil and platelet counts prior to treatment improved transiently as documented by improvements in local perfusion (laser Doppler flow and TcpO 2 in Table 3 ) and reduction in ischemic pain, but they ultimately deteriorated, and an eventual amputations could not be prevented. The acute inflammatory response manifested by an initial elevation of neutrophils and thrombocytes in circulation did not compensate for the preexisting lymphopenia and thrombocytopenia in the BMC (Table 4) . At the end, all of the amputations after AMBSC therapy in our study were secondary to infections. Based on these prognostic factors, it may be possible to clearly identify early, at the institution of ABMSC therapy, a subset of patients who are more likely to fail to cell therapy. In those patients aggressive debridement, antibiotics, grafting, and potentially pharmacological modulation of the immune sys- Figure 6 . Representative angiography of limbs before and 120 days after the ABMSC therapy. Follow-up angiography retem may be of more benefit than ABMSC treatment.
veals clear areas of neovascularization and collateral vessel
The analgesic effect of ABMSC application was seen formation along the calf vessels at the day 120 following adwithin 72 h after procedure in all patients, and was most ministration of ABMSCs. The images correspond to the palikely due to neurotransmitters (neurotrophins) release tients presented in Figure 5 with healed wounds.
(13,14,41). Patients who had a true improvement of limb perfusion following ABMSC application, and went on to heal, had a sustained pain relief and total eradication tive concentrations of other cells in the host BMC (Table  5) , providing the perfect milieu for the local enrichment of ischemic pain. All of the control patients and in patients where limb did not heal despite ABMSC treat-of the wound upon BMC transplantation (18).
Even though we found a statistically significant de-ment, pain was prominent feature throughout entire follow-up interval of 120 days. crease of CD34 + cell counts with age, advancing age did not appear to influence wound healing as would be
The results of several clinical studies suggested that assessing degree of CLI at the baseline before ABMSC expected (Fig. 1 ). This is a frequently observed phenom- could not be avoided in those with relative lymphopenia 5553-5561; 2008. and thrombocytopenia (21%). This relative difference in 10. Cipolleschi, M. G.; Dello Sbarba, P.; Olivotto, M. The lymphocyte counts was statistically different (p = 0.04 role of hypoxia in the maintenance of hematopoietic stem for BMC, p = 0.038 for BMA, and p = 0.002 for periphcells. Blood 82 (7) suggesting that intrinsic host deficiencies rather than the Goyal, P.; Bigalke, B.; Schonberger, T.; Geisler, T.; degree of disease progression was decisive.
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In conclusion, we have identified a potential mecha- 
